Focused on the discovery and clinical development of innovative biologics for unmet medical needs
Mingjiu Chen, Ph.D.
Founder, Chairman and Chief Executive Officer
Dr. Chen is the CEO of Biosion, Inc. Before establishing Biosion, Dr. Chen served as Senior Director of Monoclonal Antibody Operations at SDIX, Inc., where he led the team responsible for innovative antibody discovery services for biotech and pharmaceutical companies. Dr. Chen joined SDIX from Abbott Laboratories (now AbbVie), where he made critical contributions to several innovative biologic programs including ABT165 (now in Phase-II). Dr. Chen has over 20 years of antibody development experience in the biotech and pharmaceutic industries with expertise in competitive innovative discovery and preclinical development. Dr. Chen received his Ph.D. degree in Molecular Medicine from the University of Texas Health Science Center at San Antonio.
Hugh M. Davis, Ph.D
Chief Operating Officer & President of Biosion USA, Inc.
Dr. Davis brings to Biosion over 30 years of experience in the biotech and pharmaceutical industries. Dr. Davis joined Biosion from Frontage Laboratories, Inc., where he served as Chief Business Officer, leading the company to a very successful IPO in May of 2019. Prior to Frontage, Dr. Davis worked with Johnson & Johnson where he served as Vice President and Head of Biologics Development Sciences in the Janssen BioTherapeutics (JBIO) division of Janssen R&D, LLC since 2001. During his tenure in J&J, Hugh and his team were instrumental in the development and approval of many biologic therapies including Remicade, Stelara, Simponi, Sylvant, Darzalex and Tremfya. Prior to J&J, Hugh led the Pharmacodynamics & Exploratory Research Laboratory in the Clinical Pharmacology Unit at Glaxo SmithKline from 1996 to 2001. Dr. holds a Ph.D. degree in Biochemistry from Villanova University and completed Post-Doctoral training at Centocor, Inc. (now Janssen R&D, LLC)
Mark Ma, Ph.D.
Vice President, Head of Integrated Antibody Platform
Dr. Ma brings to Biosion over 30 years of experience in cancer biology and transgenic research, target validation and preclinical studies. Before joining Biosion, Dr. Ma served as Director of Research and Development at FZata, Inc., where he led the team responsible for developing therapeutic nanobodies to various targets. Previously, he was a faculty member at the University of Maryland and a Senior Scientist at Lexicon Pharmaceuticals, Inc. Dr. Ma received his Ph.D. degree in Biotechnology from the University of Milan, Italy and completed postdoctoral training at Baylor College of Medicine.